If Decades of History Tell Us Anything, This Biotech Near $50 Is Primed to Skyrocket

Quick Read

• Exelixis (EXEL) reported Q1 2026 numbers that bushed statement by 14.02%, with its CABOMETYX franchise increasing healthily and currency backing a $750M buyback authorization done December 2027.

• Exelixis benefits from antiaircraft superior rotation arsenic investors fly richly-valued maturation stocks toward profitable healthcare names, with a December 3, 2026 PDUFA determination connected zanzalintinib successful metastatic colorectal crab offering a near-term catalyst worthy astir $1.5B successful marketplace opportunity.

• Act now: the expert who called NVIDIA successful 2010 conscionable named his apical 10 AI stocks — and Exelixis didn't marque the cut. Grab the names FREE today.

When Wall Street's growth-at-any-price commercialized cools, superior tends to rotate toward profitable, cash-generative healthcare names, a signifier that has played retired crossed decades of monetary cycles. With the S&P 500 trading astatine affluent multiples and net expectations leaning heavy connected tech, investors hunting for under-the-radar names adjacent $50 a stock person a crushed to look astatine oncology specialists with existent currency travel alternatively than speculative pipeline-only biotechs.

With that successful mind, present is 1 biotech banal trading adjacent $50 that fits the illustration of a antiaircraft maturation sanction analysts judge inactive has country to run.

Exelixis (NASDAQ: EXEL)

Exelixis (NASDAQ:EXEL) is an oncology-focused biotechnology institution headquartered successful Alameda, California, that discovers and commercializes targeted crab therapies, astir notably CABOMETYX successful kidney, liver, and thyroid cancers.

Act now: the expert who called NVIDIA successful 2010 conscionable named his apical 10 AI stocks — and Exelixis didn't marque the cut. Grab the names FREE today.

Shares commercialized adjacent $50, aft a 12.05% summation implicit the past period and a 14.15% year-to-date advance. For a retail investor, that terms constituent inactive buys a profitable mid-cap biotech with a $12.58 cardinal marketplace capitalization alternatively than a speculative clinical-stage name.

Fundamentals backmost up the terms action. Q1 2026 non-GAAP EPS came successful astatine $0.87, beating statement by 14.02%, connected gross of $610.81 million, up 9.97% twelvemonth implicit year. Operating income jumped 34.51% and nett income climbed 31.86%. That marks 4 consecutive net beats with astonishment margins betwixt 14.02% and 17.17%.

The banal trades astatine a trailing P/E of 17 and a guardant P/E of 16, with an expert people terms of $49.65 reflecting 1 beardown buy, 9 buy, and 9 clasp ratings. H.C. Wainwright carries a $54 terms people with a Buy rating.

The bull lawsuit is straightforward. CABOMETYX is the fig 1 prescribed TKI successful renal compartment carcinoma, and planetary cabozantinib franchise gross grew 12.5% twelvemonth implicit twelvemonth to $764 cardinal successful Q1. Management is sitting connected astir $1.4 cardinal successful currency and marketable securities and conscionable authorized a caller $750 cardinal buyback moving done December 31, 2027, connected apical of completing the anterior $750 cardinal program. Layered connected apical is the December 3, 2026 PDUFA day for zanzalintinib successful antecedently treated metastatic colorectal cancer, an denotation CEO Michael Morrissey called "the apical precedence for the full Exelixis, Inc. organization," with a marketplace accidental absorption pegs astatine astir $1.5 billion. FY2026 guidance of $2.525 cardinal to $2.625 cardinal successful full gross explicitly excludes immoderate zanzalintinib motorboat contribution, leaving country for upside.